{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-023367","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2024-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.134218+00:00","generated_at":"2026-06-06T09:22:38.348461+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Tyra Biosciences announces $200M private placement led by RA Capital at $13.01/share","bullets":["Gross proceeds of approximately $200 million from sale of ~15.4 million shares/pre-funded warrants at $13.01 per share.","Financing led by RA Capital Management with participation from Boxer Capital, BVF Partners, Nextech, OrbiMed, 5AM Ventures.","Proceeds to advance clinical development of TYRA-300 and TYRA-200, preclinical programs, and for working capital.","PIPE expected to close on February 6, 2024, subject to customary closing conditions.","Company to file resale registration statement with SEC within 45 days after closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-023367","json":"https://secwatch.observer/filing/0001193125-24-023367.json","markdown":"https://secwatch.observer/filing/0001193125-24-023367.md","text":"https://secwatch.observer/filing/0001193125-24-023367.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312524023367/0001193125-24-023367-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312524023367/d620082d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:22:38.348461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d394598fc527d03ebe9ccf49c7ca89317831fd7","claim":"Tyra Biosciences, Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $200 million (effective 2024-02-01).","evidence_excerpt":"On February 1, 2024, Tyra Biosciences, Inc. (the Company) entered into a securities purchase agreement (the Purchase Agreement) with the purchasers named therein (the Purchasers), for the private placement (the Private Placement) of (i) 9,286,023 shares (the Shares) of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312524023367/0001193125-24-023367-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the purchasers named therein"},{"label":"Value","value":"approximately $200 million"},{"label":"Effective","value":"2024-02-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}